Edesa Biotech, Inc.

Edesa Biotech is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immune-related diseases. The company acquires, develops, and commercializes drug candidates that demonstrate biological proof-of-concept in human subjects. Its development pipeline centers on two main therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, the company develops EB06, an anti-CXCL10 monoclonal antibody for vitiligo, and EB01, a topical cream for chronic allergic contact dermatitis. In Respiratory, its primary candidate is EB05 (paridiprubart), a toll-like receptor 4 inhibitor designed to treat acute respiratory distress syndrome. Its targeted patient populations include individuals suffering from respiratory failure and inflammatory skin conditions.

The company conducts clinical development activities and regulatory trials primarily across the United States and Canada, operating in part through its subsidiary, Edesa Biotech Research, Inc. Its research and target opportunities span major international markets including North America, Europe, and Japan. The provided text does not disclose the specific headquarters city or location, nor does it state the company's founding year or website address.

Summary of the business section of Edesa Biotech's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of the date of this filing, we have 17 full-time employees: ten employees are primarily engaged in research and development, and seven employees are engaged in management, administration, business development and finance.”